Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1490273
European Journal of Endocrinology, Vol 149, Issue 4, 273-285
Copyright © 2003 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barzon, L
Right arrow Articles by Boscaro, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barzon, L
Right arrow Articles by Boscaro, M

Articles

Prevalence and natural history of adrenal incidentalomas

L Barzon, N Sonino, F Fallo, G Palu, and M Boscaro

Department of Histology, Microbiology, and Medical Biotechnologies, University of Padua, Via Gabelli 63, 35121 Padua, Italy. luisa.barzon@unipd.it

Clinically silent adrenal masses discovered by imaging studies performed for unrelated reasons, i.e. adrenal incidentalomas, have become a rather common finding in clinical practice. However, only limited studies of incidence, prevalence, and natural history of adrenal incidentalomas are available. A comprehensive review of the literature shows the prevalence of adrenal incidentalomas to be 2.3% at autopsy and 0.5-2% at abdominal computed tomography scan. Most lesions are adrenocortical adenomas at histology, whereas the prevalence of adrenocortical carcinomas is relatively low. The risk of malignancy over time for masses defined as benign at diagnosis is estimated at about 1/1000, even though 5-25% of masses increase in size during follow-up. Hyperfunction develops in about 1.7% of cases and the risk is higher in patients with lesions larger than 3 cm. Cortisol hypersecretion is the most likely disorder that may ensue, and it remains subclinical in about two-thirds of cases. The lack of controlled studies precludes making specific management recommendations. Large perspective controlled studies to define the epidemiology, natural history, and possible associated morbidity of adrenal incidentalomas and their impact on the quality of life of patients are needed.


This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
P K Singh and H N Buch
Adrenal incidentaloma: evaluation and management
J. Clin. Pathol., November 1, 2008; 61(11): 1168 - 1173.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. W. Funder, R. M. Carey, C. Fardella, C. E. Gomez-Sanchez, F. Mantero, M. Stowasser, W. F. Young Jr., and V. M. Montori
Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3266 - 3281.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Hahner, A. Stuermer, M. Kreissl, C. Reiners, M. Fassnacht, H. Haenscheid, F. Beuschlein, M. Zink, K. Lang, B. Allolio, et al.
[123I]Iodometomidate for Molecular Imaging of Adrenocortical Cytochrome P450 Family 11B Enzymes
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2358 - 2365.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
J. H. Song, F. S. Chaudhry, and W. W. Mayo-Smith
The Incidental Adrenal Mass on CT: Prevalence of Adrenal Disease in 1,049 Consecutive Adrenal Masses in Patients with No Known Malignancy
Am. J. Roentgenol., May 1, 2008; 190(5): 1163 - 1168.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
J. H. Song, F. S. Chaudhry, and W. W. Mayo-Smith
The Incidental Indeterminate Adrenal Mass on CT (> 10 H) in Patients Without Cancer: Is Further Imaging Necessary? Follow-Up of 321 Consecutive Indeterminate Adrenal Masses
Am. J. Roentgenol., November 1, 2007; 189(5): 1119 - 1123.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
I. Chiodini, M. L. Mascia, S. Muscarella, C. Battista, S. Minisola, M. Arosio, S. A. Santini, G. Guglielmi, V. Carnevale, and A. Scillitani
Subclinical Hypercortisolism among Outpatients Referred for Osteoporosis
Ann Intern Med, October 16, 2007; 147(8): 541 - 548.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
L. K. Nieman
Screening for Reversible Osteoporosis: Is Cortisol a Culprit?
Ann Intern Med, October 16, 2007; 147(8): 582 - 584.
[Full Text] [PDF]


Home page
Cancer Res.Home page
A. Horvath, C. Giatzakis, A. Robinson-White, S. Boikos, E. Levine, K. Griffin, E. Stein, V. Kamvissi, P. Soni, I. Bossis, et al.
Adrenal Hyperplasia and Adenomas Are Associated with Inhibition of Phosphodiesterase 11A in Carriers of PDE11A Sequence Variants That Are Frequent in the Population
Cancer Res., December 15, 2006; 66(24): 11571 - 11575.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Allolio and M. Fassnacht
Adrenocortical Carcinoma: Clinical Update
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2027 - 2037.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
H J Lehtonen, M Kiuru, S K Ylisaukko-oja, R Salovaara, R Herva, P A Koivisto, O Vierimaa, K Aittomaki, E Pukkala, V Launonen, et al.
Increased risk of cancer in patients with fumarate hydratase germline mutation
J. Med. Genet., June 1, 2006; 43(6): 523 - 526.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
B. Bulow, S. Jansson, C. Juhlin, L. Steen, M. Thoren, H. Wahrenberg, S. Valdemarsson, B. Wangberg, B. Ahreen, and on behalf of the Swedish Research Council Study Gr
Adrenal incidentaloma - follow-up results from a Swedish prospective study.
Eur. J. Endocrinol., March 1, 2006; 154(3): 419 - 423.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
I. Chiodini, M. Torlontano, A. Scillitani, M. Arosio, S. Bacci, S. Di Lembo, P. Epaminonda, G. Augello, R. Enrini, B. Ambrosi, et al.
Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients
Eur. J. Endocrinol., December 1, 2005; 153(6): 837 - 844.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
D Montanaro, M Maggiolini, A G Recchia, R Sirianni, S Aquila, L Barzon, F Fallo, S Ando, and V Pezzi
Antiestrogens upregulate estrogen receptor {beta} expression and inhibit adrenocortical H295R cell proliferation
J. Mol. Endocrinol., October 1, 2005; 35(2): 245 - 256.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. Terzolo, S. Bovio, A. Pia, P. A. Conton, G. Reimondo, C. Dall'Asta, D. Bemporad, A. Angeli, G. Opocher, M. Mannelli, et al.
Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma
Eur. J. Endocrinol., August 1, 2005; 153(2): 307 - 315.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Thorin-Savoure, F. Tissier-Rible, L. Guignat, A. Pellerin, X. Bertagna, J. Bertherat, and H. Lefebvre
Collision/Composite Tumors of the Adrenal Gland: A Pitfall of Scintigraphy Imaging and Hormone Assays in the Detection of Adrenal Metastasis
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4924 - 4929.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
J. Yee, N. N. Kumar, S. Godara, J. A. Casamina, R. Hom, G. Galdino, P. Dell, and D. Liu
Extracolonic Abnormalities Discovered Incidentally at CT Colonography in a Male Population
Radiology, August 1, 2005; 236(2): 519 - 526.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 European Society of Endocrinology.